The Medical Letter - Issue 1717 | The Medical Letter Inc.

The Medical Letter on Drugs and Therapeutics

FROM
ISSUE

1717

December 9, 2024

View Complete Issue Table of Contents 2019

Issue 1717

Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.

Antiviral Drugs for Seasonal Influenza for 2024-2025

December 9, 2024 (Issue: 1717)

Influenza is generally a self-limited illness, but pneumonia, respiratory failure, and death can occur, especially in persons at increased risk for influenza complications (see Table 1). Updated information on influenza activity and antiviral...more

Show References Hide References

CDC. Influenza antiviral medications: summary for clinicians. December 8, 2023. Available at: https://bit.ly/48KeAna. Accessed November 21, 2024.
TM Uyeki et al. Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis 2019; 68:895. doi:10.1093/cid/ciy874
Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2024-2025: policy statement. Pediatrics 2024; 154:e2024068507. doi:10.1542/peds.2024-068507
CDC. Information for clinicians on rapid diagnostic testing for influenza. September 17, 2024. Available at: https://bit.ly/3Z3LvjE. Accessed November 21, 2024.
JP Metlay et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019; 200:e45. doi:10.1164/rccm.201908-1581st
CC Butler et al. Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial. Lancet 2020; 395:42. doi:10.1016/s0140-6736(19)32982-4
IDSA. IDSA statement on neuraminidase inhibitors. Available at: http://bit.ly/34AdhEU. Accessed November 21, 2024.
FG Hayden et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med 2018; 379:913. doi:10.1056/nejmoa1716197
MG Ison et al. Early treatment with baloxavir marboxil in highrisk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis 2020; 20:1204. doi:10.1016/S1473-3099(20)30004-9
In brief: Concerns about oseltamivir (Tamiflu). Med Lett Drugs Ther 2015; 57:14.
MK Doll et al. Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: a systematic review of systematic reviews and/or meta-analyses. J Antimicrob Chemother 2017; 72:2990. doi:10.1093/jac/dkx271
J Katzen et al. Early oseltamivir after hospital admission is associated with shortened hospitalization: a 5-year analysis of oseltamivir timing and clinical outcomes. Clin Infect Dis 2019; 69:52. doi:10.1093/cid/ciy860
Y Sharma et al. Effectiveness of oseltamivir in reducing 30-day readmissions and mortality among patients with severe seasonal influenza in Australian hospitalized patients. Int J Infect Dis 2021; 104:232. doi:10.1016/j.ijid.2021.01.011
J Baker et al. Baloxavir marboxil single-dose treatment in influenza-infected children: a randomized, double-blind, active controlled phase 3 safety and efficacy trial (miniSTONE-2). Pediatr Infect Dis J 2020; 39:700. doi:10.1097/inf.0000000000002747
RE Malosh et al. Efficacy and safety of oseltamivir in children: systematic review and individual patient data meta-analysis of randomized controlled trials. Clin Infect Dis 2018; 66:1492. doi:10.1093/cid/cix1040
JS Lee et al. Clinical effectiveness of intravenous peramivir versus oseltamivir for the treatment of influenza in hospitalized patients. Infect Drug Resist 2020; 13:1479. doi:10.2147/idr. s247421
Y Gao et al. Antivirals for treatment of severe influenza: a systematic review and network meta-analysis of randomised controlled trials. Lancet 2024; 404:753. doi:10.1016/s0140-6736(24)01307-2
AP Campbell et al. Influenza antiviral treatment and length of stay. Pediatrics 2021; 148:e2021050417. doi:10.1542/peds.2021-050417
D Kumar et al. Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalized with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial. Lancet Infect Dis 2022; 22:718. doi:10.1016/s1473-3099(21)00469-2
JK Louie et al. Neuraminidase inhibitors for critically ill children with influenza. Pediatrics 2013; 132:e1539. doi:10.1542/peds.2013-2149
SG Muthuri et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014; 2:395. doi:10.1016/s2213-2600(14)70041-4
JK Louie et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis 2012; 55:1198. doi:10.1093/cid/cis636
MW Tenforde et al. Timing of influenza antiviral therapy and risk of death in adults hospitalized with influenza-associated pneumonia, influenza hospitalization surveillance network (FluServ-NET), 2012-2019. Clin Infect Dis 2024 August 22 (epub). doi:10.1093/cid/ciae427
H Ikematsu et al. Baloxavir marboxil for prophylaxis against influenza in household contacts. N Engl J Med 2020; 383:309. doi:10.1056/nejmoa1915341
Y Zhao et al. Antivirals for post-exposure prophylaxis of influenza: a systematic review and network meta-analysis. Lancet 2024; 404:764. doi:10.1016/s0140-6736(24)01357-6
EJ Chow et al. Clinical effectiveness and safety of antivirals for influenza in pregnancy. Open Forum Infect Dis 2021; 8:ofab138. doi:10.1093/ofid/ofab138
V Ehrenstein et al. Oseltamivir in pregnancy and birth outcomes. BMC Infect Dis 2018; 18:519. doi:10.1186/s12879-018-3423-z
American College of Obstetricians and Gynecologists. Influenza in pregnancy: prevention and treatment: ACOG Committee Statement No. 7. Obstet Gynecol 2024; 143:e24. doi:10.1097/aog.0000000000005479
CDC. Recommendations for obstetric health care providers related to use of antiviral medications for the treatment and prevention of influenza. September 15, 2022. Available at: https://bit.ly/3O62Xxx. Accessed November 21, 2024.
IK Oboho et al. Benefit of early initiation of influenza antiviral treatment to pregnant women hospitalized with laboratory-confirmed influenza. J Infect Dis 2016; 214:507. doi:10.1093/infdis/jiw033
EA Govorkova et al. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018-2020. Antiviral Res 2022; 200:105281. doi:10.1016/j.antiviral.2022.105281
AC Hurt et al. Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia. J Infect Dis 2012; 206:148. doi:10.1093/infdis/jis337
C Renaud et al. H275Y mutant pandemic (H1N1) 2009 virus in immunocompromised patients. Emerg Infect Dis 2011; 17:653. doi:10.3201/eid1704.101429
JW Tang et al. Transmitted and acquired oseltamivir resistance during the 2018-2019 influenza season. J Infect 2019; 79:612. doi:10.1016/j.jinf.2019.10.020
R Roosenhoff et al. Viral kinetics and resistance development in children treated with neuraminidase inhibitors: the Influenza Resistance Information Study (IRIS). Clin Infect Dis 2020; 71:1186. doi:10.1093/cid/ciz939
B Lina et al. Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study. Influenza Other Respir Viruses 2018; 12:267. doi:10.1111/irv.12534
E Takashita et al. Influenza A(H1N1)pdm09 virus exhibiting enhanced cross-resistance to oseltamivir and peramivir due to a dual H275Y/G147R substitution, Japan, March 2016. Euro Surveill 2016; 21:pii=30258. doi:10.2807/1560-7917. es.2016.21.24.30258
R Trebbien et al. Development of oseltamivir and zanamivir resistance in influenza A(H1N1)pdm09 virus, Denmark, 2014. Euro Surveill 2017; 22:30445. doi:10.2807/1560-7917.es.2017.22.3.30445
E Mitha et al. Safety, resistance, and efficacy results from a phase IIIb study of conventional- and double-dose oseltamivir regimens for treatment of influenza in immunocompromised patients. Infect Dis Ther 2019; 8:613. doi:10.1007/s40121-019-00271-8
T Uehara et al. Treatment-emergent influenza variant viruses with reduced baloxavir susceptibility: impact on clinical and virologic outcomes in uncomplicated influenza. J Infect Dis 2020; 221:346. doi:10.1093/infdis/jiz244
E Takashita et al. Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019. Euro Surveill 2019; 24:1900170. doi:10.2807/1560-7917.es.2019.24.12.1900170
E Takashita et al. Human-to-human transmission of influenza A(H3N2) virus with reduced susceptibility to baloxavir, Japan, February 2019. Emerg Infect Dis 2019; 25:2108. doi:10.3201/eid2511.190757
M Seki et al. Adult influenza A (H3N2) with reduced susceptibility to baloxavir or peramivir cured after switching anti-influenza agents. IDCases 2019; 18:e00650. doi:10.1016/j.idcr.2019. e00650
R MacLaren et al. Oseltamivir-associated bradycardia in critically ill patients. Ann Pharmacother 2021; 55:1318. doi:10.1177/1060028020988919
Peramivir (Rapivab): an IV neuraminidase inhibitor for treatment of influenza. Med Lett Drugs Ther 2015; 57:17.
Baloxavir marboxil (Xofluza) for treatment of influenza. Med Lett Drugs Ther 2018; 60:193.
S Toovey et al. Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: an updated review. Adv Ther 2012; 29:826. doi:10.1007/s12325-012-0050-8
Influenza vaccine for 2024-2025. Med Lett Drugs Ther 2024; 66:145.
LA Grohskopf et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices – United States, 2024-25 influenza season. MMWR Recomm Rep 2024; 73:1. doi:10.15585/mmwr.rr7305a1

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue? Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:

Print version published and mailed biweekly (26 issues/year)
Unlimited online access to current and past issues (1988 - present)
Mobile App
FREE online per issue CME/CE

Purchase this issue:

Title: Issue 1717

Gain access through your organization

Ask your librarian to consider an Institutional Subscription to The Medical Letter.

Recommend to your librarian